Abstract
Most patients hospitalized for acutely decompensated heart failure (ADHF) present with symptoms and signs of volume overload, which are also associated with high rates of death and re-hospitalization. Several studies have investigated the possible use of extracorporeal ultrafiltration in the management of ADHF, evaluating potential clinical benefits in terms of hospitalization and survival rates versus those of conventional diuretic therapy. Though ultrafiltration remains an extremely appealing therapeutic option for patients with AHDF, some of the most recent studies have reported conflicting results. Differences in the selection of study population, heterogeneity of the indications for the use of ultrafiltration, disparity in the ultrafiltration protocols, and high variability in the pharmacologic therapies used for the control group could explain some of these contradictory findings. The purpose of the present review is to provide an overview and an update on the mechanisms and clinical effects of ultrafiltration and on currently available evidence supporting its use in ADHF.
| Original language | English |
|---|---|
| Pages (from-to) | 103-112 |
| Number of pages | 10 |
| Journal | American Journal of Cardiovascular Drugs |
| Volume | 15 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Cardiology and Cardiovascular Medicine
- Medicine(all)
Cite this
Continuous Ultrafiltration in Acute Decompensated Heart Failure : Current Issues and Future Directions. / Marenzi, Giancarlo; Morpurgo, Marco; Agostoni, Piergiuseppe.
In: American Journal of Cardiovascular Drugs, Vol. 15, No. 2, 01.04.2015, p. 103-112.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Continuous Ultrafiltration in Acute Decompensated Heart Failure
T2 - Current Issues and Future Directions
AU - Marenzi, Giancarlo
AU - Morpurgo, Marco
AU - Agostoni, Piergiuseppe
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Most patients hospitalized for acutely decompensated heart failure (ADHF) present with symptoms and signs of volume overload, which are also associated with high rates of death and re-hospitalization. Several studies have investigated the possible use of extracorporeal ultrafiltration in the management of ADHF, evaluating potential clinical benefits in terms of hospitalization and survival rates versus those of conventional diuretic therapy. Though ultrafiltration remains an extremely appealing therapeutic option for patients with AHDF, some of the most recent studies have reported conflicting results. Differences in the selection of study population, heterogeneity of the indications for the use of ultrafiltration, disparity in the ultrafiltration protocols, and high variability in the pharmacologic therapies used for the control group could explain some of these contradictory findings. The purpose of the present review is to provide an overview and an update on the mechanisms and clinical effects of ultrafiltration and on currently available evidence supporting its use in ADHF.
AB - Most patients hospitalized for acutely decompensated heart failure (ADHF) present with symptoms and signs of volume overload, which are also associated with high rates of death and re-hospitalization. Several studies have investigated the possible use of extracorporeal ultrafiltration in the management of ADHF, evaluating potential clinical benefits in terms of hospitalization and survival rates versus those of conventional diuretic therapy. Though ultrafiltration remains an extremely appealing therapeutic option for patients with AHDF, some of the most recent studies have reported conflicting results. Differences in the selection of study population, heterogeneity of the indications for the use of ultrafiltration, disparity in the ultrafiltration protocols, and high variability in the pharmacologic therapies used for the control group could explain some of these contradictory findings. The purpose of the present review is to provide an overview and an update on the mechanisms and clinical effects of ultrafiltration and on currently available evidence supporting its use in ADHF.
UR - http://www.scopus.com/inward/record.url?scp=84926393272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926393272&partnerID=8YFLogxK
U2 - 10.1007/s40256-015-0107-6
DO - 10.1007/s40256-015-0107-6
M3 - Article
C2 - 25650293
AN - SCOPUS:84926393272
VL - 15
SP - 103
EP - 112
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
SN - 1175-3277
IS - 2
ER -